JP2015503620A5 - - Google Patents

Download PDF

Info

Publication number
JP2015503620A5
JP2015503620A5 JP2014552311A JP2014552311A JP2015503620A5 JP 2015503620 A5 JP2015503620 A5 JP 2015503620A5 JP 2014552311 A JP2014552311 A JP 2014552311A JP 2014552311 A JP2014552311 A JP 2014552311A JP 2015503620 A5 JP2015503620 A5 JP 2015503620A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
hydrogen
membered
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014552311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015503620A (ja
JP6109195B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/021093 external-priority patent/WO2013106612A1/en
Publication of JP2015503620A publication Critical patent/JP2015503620A/ja
Publication of JP2015503620A5 publication Critical patent/JP2015503620A5/ja
Application granted granted Critical
Publication of JP6109195B2 publication Critical patent/JP6109195B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014552311A 2012-01-13 2013-01-11 キナーゼ阻害剤として有用な複素環置換されたピリジル化合物 Expired - Fee Related JP6109195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586155P 2012-01-13 2012-01-13
US61/586,155 2012-01-13
PCT/US2013/021093 WO2013106612A1 (en) 2012-01-13 2013-01-11 Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2015503620A JP2015503620A (ja) 2015-02-02
JP2015503620A5 true JP2015503620A5 (cg-RX-API-DMAC10.html) 2016-02-12
JP6109195B2 JP6109195B2 (ja) 2017-04-05

Family

ID=47595097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014552311A Expired - Fee Related JP6109195B2 (ja) 2012-01-13 2013-01-11 キナーゼ阻害剤として有用な複素環置換されたピリジル化合物

Country Status (6)

Country Link
US (1) US9242975B2 (cg-RX-API-DMAC10.html)
EP (1) EP2802576B1 (cg-RX-API-DMAC10.html)
JP (1) JP6109195B2 (cg-RX-API-DMAC10.html)
CN (1) CN104159896B (cg-RX-API-DMAC10.html)
ES (1) ES2686500T3 (cg-RX-API-DMAC10.html)
WO (1) WO2013106612A1 (cg-RX-API-DMAC10.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2903617B1 (en) * 2012-10-08 2019-01-30 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
SG11201503397YA (en) 2012-11-08 2015-05-28 Bristol Myers Squibb Co Heteroaryl substituted pyridyl compounds useful as kinase modulators
JP6215338B2 (ja) 2012-11-08 2017-10-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
TW201609693A (zh) 2014-01-03 2016-03-16 必治妥美雅史谷比公司 雜芳基取代之菸鹼醯胺化合物
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
UY36749A (es) 2015-06-24 2016-12-30 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen
AR105114A1 (es) * 2015-06-24 2017-09-06 Bristol Myers Squibb Co Compuestos de aminopiridina sustituida con heteroarilo
TW201718571A (zh) * 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
CN115448916A (zh) * 2016-10-14 2022-12-09 林伯士拉克许米公司 Tyk2抑制剂及其用途
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
WO2018165338A2 (en) * 2017-03-07 2018-09-13 uBiome, Inc. Therapeutic & diagnostics compositions targeting toll-like receptors and methods thereof
KR102604900B1 (ko) * 2017-05-11 2023-11-21 브리스톨-마이어스 스큅 컴퍼니 Irak4 억제제로서 유용한 티에노피리딘 및 벤조티오펜
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
MX2020003190A (es) 2017-09-22 2020-11-11 Kymera Therapeutics Inc Degradadores de proteinas y usos de los mismos.
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
AU2018388404B2 (en) 2017-12-22 2023-11-02 HiberCell Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
TWI727392B (zh) * 2018-08-13 2021-05-11 美商基利科學股份有限公司 噻二唑irak4抑制劑
KR102329235B1 (ko) 2018-11-21 2021-11-22 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
WO2020106059A1 (ko) 2018-11-21 2020-05-28 한국화학연구원 Irak4 저해제로서 신규의 삼중고리 화합물
BR112021010484A2 (pt) 2018-11-30 2021-08-24 Kymera Therapeutics, Inc. Degradadores de irak e usos dos mesmos
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
EP3999512B1 (en) 2019-07-18 2023-08-23 Bristol-Myers Squibb Company Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as irak4 inhibitors
JP7570399B2 (ja) 2019-07-18 2024-10-21 ブリストル-マイヤーズ スクイブ カンパニー Irak4阻害剤として有用な三環式ヘテロアリール化合物
EP4004000B1 (en) 2019-07-23 2025-07-09 Bristol-Myers Squibb Company Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors
EP4010317B1 (en) 2019-08-06 2024-06-19 Bristol-Myers Squibb Company Bicyclic heterocyclic compounds useful as irak4 inhibitors
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN115052627A (zh) 2019-12-17 2022-09-13 凯麦拉医疗公司 Irak降解剂和其用途
US12391702B2 (en) 2020-02-03 2025-08-19 Bristol-Myers Squibb Company Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors
CN115335380B (zh) 2020-02-03 2024-08-02 百时美施贵宝公司 可用作irak4抑制剂的三环杂芳基化合物
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
CN116867758A (zh) 2020-12-30 2023-10-10 凯麦拉医疗公司 Irak降解剂和其用途
AU2022220043A1 (en) 2021-02-15 2023-08-31 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
WO2023076556A1 (en) 2021-10-29 2023-05-04 Kymera Therapeutics, Inc. Irak4 degraders and synthesis thereof
WO2023147594A2 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2026005537A1 (ko) * 2024-06-28 2026-01-02 주식회사 대웅제약 신규한 화합물, 및 이를 포함하는 암 또는 자가 면역 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102800A1 (en) 2001-06-15 2002-12-27 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
GB0211019D0 (en) 2002-05-14 2002-06-26 Syngenta Ltd Novel compounds
US7449456B2 (en) 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative
ATE433967T1 (de) 2003-01-17 2009-07-15 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
CN1820001A (zh) 2003-07-10 2006-08-16 神经能质公司 经取代的杂环二芳基胺类似物
GB0402653D0 (en) 2004-02-06 2004-03-10 Cyclacel Ltd Compounds
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
FR2896503B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CA2663091A1 (en) * 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Modulators of interleukin-1 receptor-associated kinase
AU2007334436A1 (en) * 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
RU2471793C2 (ru) 2007-06-08 2013-01-10 Байер Кропсайенс Аг Фунгицид на основе гетероциклил-пиримидинил-аминопроизводных
WO2009046416A1 (en) 2007-10-05 2009-04-09 Targegen Inc. Anilinopyrimidines as jak kinase inhibitors
GB0719644D0 (en) * 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2010144647A1 (en) 2009-06-12 2010-12-16 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
JP2012254939A (ja) * 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
CA2778979C (en) 2009-10-30 2018-04-24 Janssen Pharmaceutica Nv Phenoxy-substituted pyrimidines as opioid receptor modulators
EP2532656A1 (en) 2010-02-01 2012-12-12 Nippon Chemiphar Co., Ltd. Gpr119 agonist
AU2012249240A1 (en) 2011-04-29 2013-11-07 Icahn School Of Medicine At Mount Sinai Kinase inhibitors
JP6096807B2 (ja) 2012-01-13 2017-03-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company キナーゼ阻害剤として有用なトリアゾリル置換されたピリジル化合物
EP2802579B1 (en) 2012-01-13 2016-04-13 Bristol-Myers Squibb Company Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2015503620A5 (cg-RX-API-DMAC10.html)
JP2015503621A5 (cg-RX-API-DMAC10.html)
JP2015503622A5 (cg-RX-API-DMAC10.html)
JP2009263394A5 (cg-RX-API-DMAC10.html)
JP2016506368A5 (cg-RX-API-DMAC10.html)
RU2019131111A (ru) ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ
JP2016501185A5 (cg-RX-API-DMAC10.html)
JP2016513660A5 (cg-RX-API-DMAC10.html)
JP2019527718A5 (cg-RX-API-DMAC10.html)
JP2015504076A5 (cg-RX-API-DMAC10.html)
RU2020123151A (ru) Антагонисты tlr7/8 и их применение
JP2017509689A5 (cg-RX-API-DMAC10.html)
JP2017527561A5 (cg-RX-API-DMAC10.html)
JP2015520140A5 (cg-RX-API-DMAC10.html)
JP2013507425A5 (cg-RX-API-DMAC10.html)
JP2016504365A5 (cg-RX-API-DMAC10.html)
JP2005535586A5 (cg-RX-API-DMAC10.html)
JP2013534245A5 (cg-RX-API-DMAC10.html)
JP2014510727A5 (cg-RX-API-DMAC10.html)
ME02221B (me) Postupak za proizvodnju intermedijara jedinjenja korisnih kao modulatori opioidnih receptora
JP2017533968A5 (cg-RX-API-DMAC10.html)
CN102186833A (zh) Mif调节剂
JP2017501237A5 (cg-RX-API-DMAC10.html)
JP2016537382A5 (cg-RX-API-DMAC10.html)
JP2014518543A5 (cg-RX-API-DMAC10.html)